International Journal of Research in Pharmacy and Pharmaceutical Sciences
www.pharmacyjournal.in
ISSN: 2455-698X
Received: 20-05-2022, Accepted: 05-06-2022, Published: 21-06-2022
Volume 7, Issue 2, 2022, Page No. 52-60

A review on neuropharmacology of schizophrenia

Akshada V Avhad*, Laxmikant B Borse, Atul Bendale, Anil G Jadhav
Sandip Foundation's, Sandip Institute of Pharmaceutical Sciences, Nashik, Maharashtra, India

Abstract
Schizophrenia is a prevalent complex condition marked by psychosis, cognitive impairment, and unpleasant symptoms, with an aetiology that includes interactions between genetic, mental and environmental risk factors. Recent findings from continuing research into the nature of these vulnerability elements have proved promising. The progress made in the understanding of environmental risk factors for mental disorders, genetic studies into mental illnesses, are to be discussed. The findings' limitations will be highlighted, as well as the implications of these developments for genetic counselling practise. Over the last half-century, the development of antipsychotic medications has had a significant impact on the treatment of schizophrenia. Many second-generation antipsychotics (atypical and dopamine partial agonist) are thought to have advantage over first-generation medications for treating schizophrenia.The Neurodevelopment Hypothesis, Dopamine Hypothesis, and Glutamate Hypothesis are three proposed biological theories for schizophrenia. It's critical to assist someone with schizophrenia symptoms in receiving treatment as soon as feasible. Here Antipsychotic medicines and psychosocial therapy are two types of treatments that can help with symptoms.Various drugs have been discussed in the review like Clozapine, Paliperidone, Asenapine, Lurasidone, Olanzapine, Quetiapine, Ziprasidone, Risperdal.

Keywords: schizophrenia; genetic vulnerability; environmental vulnerability; genetic counseling issues, antipsychotics, glutamate hypothesis

Introduction
Schizo is a term that refers to a split ad. Phrenia is a word that signifies "splitting of the Mind."
Splitting the mind, on the other hand, does not signify splitting the personality; rather, it refers to a spread or fractured pattern of thought. Schizophrenia is a syndrome, which means there are a variety of symptoms that might be associated with it, and different patients may have different symptoms.
Schizophrenia is the typical illness for the "psychotic disorder" group of mental illness. Psychosis is a term used to define a variety of cognitive disorders, as well as a frequently distorted perspective of reality. These can include hallucination, which is sensory perception without actual stimuli, such as hearing or seeing things that aren't there, or delusions, which are fixed incorrect beliefs that aren't explained by a person's culture, such as the assumption that someone else is guiding one's thinking. Hallucinations are non-shared perceptual experiences that can affect any of the five senses and are not restricted to visual interactions.
A chronic mental illness marked by a breakdown in the relationship between thought, emotion, and behaviour, resulting to incorrect perceptions, inappropriate actions, and feelings, as well as a sense of mental fragmentation and withdrawal from reality and personal relationships into fantasy and delusions. Schizophrenia is the result of a complex interaction between thousands of genes and several environmental risk factors.
This condition has a worldwide rate of only 1%, which is extremely low. Men are more prone to develop the condition in their late teens or early twenties, while women are more likely to develop it in their late 20s or early 30s.
Schizophrenia appears to be a polygenic condition in which environmental and developmental factors have a role in a person's ability to become schizophrenic. Genetics has been found to play a significant impact in schizophrenia, according to studies. The condition is a reflection of two characteristics of schizophrenia: (a) the disorder frequently begins in early adulthood, and (b) roughly two-thirds of those who are diagnosed have persistent or fluctuating symptoms despite receiving appropriate therapy.

Causes of Schizophrenia
In persons with schizophrenia, differences in a brain component called neurotransmitter are frequent (controls communication in the brain). Neurotransmitters are either too active or not active enough in people with schizophrenia.
People suffering from schizophrenia recognised this. a) The ventricles, or brain spaces, are bigger. (b) The memory-related medial temporal lobes of the brain were smaller. (c) The number of connections between neurons in the brain is reducing.

A mild, generalised loss in grey matter, a minor reduction in overall brain volume, enlargement of ventricles, and specific change of white matter tracts have all been observed in studies. Neuropathological studies have discovered evidence for cytoarchitectural abnormalities in places like the hippocampus and prefrontal cortex, where volume reduction is more severe. Despite the fact that this physical pathology is minor, it has been related to problems in a variety of cortical sites. Patients' activation in a number of cortical and subcortical regions, including the prefrontal and parietal cortices, as well as the thalamus, was reduced by simple auditory and sensory inputs. Prenatal and postnatal problems, as well as environmental exposure, appear to have a greater impact than individual genes, with prenatal infection or hypoxia increasing the chance of schizophrenia from 1 in 100 to 2-4 in 100. Recent studies have tried to describe the relationship between genetic risk and environmental exposure that is thought to be the cause of schizophrenia. Furthermore, research has shown that if one of the parents has a psychotic illness, maternal sadness during pregnancy increases the risk of schizophrenia in the kids. If one parent has psychosis, a child's risk of developing schizophrenia increases by 2.6 times. Maternal depression did not increase the risk of schizophrenia on its own, but it was more than 9 times more likely when it was combined with environmental risk factors for maternal depression. When genetic risk and environmental exposure are combined, the risk of schizophrenia rises more than would be expected if the hazards were added separately.

The polygenic interaction of several common variants of hundreds of genes, each with a very modest effect, is thought to be the first way that genetic risk for schizophrenia originates.

The second are rare but highly penetrant genetic events such as deletion or duplication-copy number variation of prenatal and perinatal environmental risk factors; three of the gene environment studies related to schizophrenia focus on these-infection, depression/stress, and urban birth.

Schizophrenia is caused by an abnormal synapse and circuit formation development trajectory, which results in a brain that is miswired and shows clinical symptoms. This abnormal developmental trajectory is caused by the interaction of thousands of risk genes and different environmental risk factors. One way is to learn more about the effects of risk genes in brain development, which is the subject of several current studies. A similar strategy is used to investigate how environmental risk factors affect the developing brain. Environmental risk factors, which can be avoided whereas inherited risk factors cannot, may provide the best chance for prevention in the end. This illness could be the one-of-a-kind price we as a species pay for the complexity of our brains; in the end, some people, more or less by hereditary and environmental chance, develop this illness.

The most recent research indicates a gene-environment interaction that is similar to the risk of schizophrenia, such as the connection between genetic vulnerability and prenatal infection, urban birth, and cannabis use and a catechol-O-methyltransferase polymorphism. Stress can have a range of effects on brain development that may increase the risk of schizophrenia, according to evidence from clinical and preclinical research. In rhesus monkeys, for example, prenatal maternal stress causes decreased hippocampus volume and

Neurogenesis.

- It has been discovered that virus exposure has a role in the development of schizophrenia. A variety of virus characteristics could make this possible. Viruses, for
- Example, can target specific brain regions while leaving others unaffected.
- Change the way specific processes in a brain cell work without destroying it.
- Infect someone and then go dormant for years before producing disease.
- In people with schizophrenia, minor physical defects, birth problems, and changed fingerprint patterns are common.

Symptoms of schizophrenia

Positive, negative, and cognitive symptoms are the three primary kinds of Psychopathological symptoms associated with this disorder. Despite the fact that positive and cognitive symptoms are almost universal in schizophrenia, positive

Symptoms have not been linked to cognitive changes.

Positive symptoms

Positive symptoms usually appear in young adulthood, while cognitive problems might appear at any age (11, 12). Psychosis is a chronic illness with symptoms that can last for months or years, and only a small percentage of people recover completely. Auditory, visual, olfactory, gustatory, and tactile hallucinations all occur in schizophrenia, with auditory hallucination being the most common. Persecutory delusions, delusion of control (e.g., the belief that one's thoughts or actions are controlled by others), grandiose delusion (e.g., the thought that one is god), and somatic delusion are all examples of delusions in schizophrenia. These symptoms may appear in waves over time. "Delusions and prominent hallucinations, with the hallucination happening in the absence of understanding into their pathological character," is the most typical definition. In addition to delusions and hallucinations, the alternative definition includes "additional positive signs of schizophrenia

(Disorganized mental process, and severely disorganized or cationic behavior)."

Negative symptoms

Blunted affects (e.g., immovable facial expression, monotonous voice tone), anhedonia (lack of pleasure), and alogia are all common unfavorable symptoms (reduced quantity and content of speech). Positive psychotic

symptoms are more widespread and fluctuate less over time than negative psychotic symptoms. Negative symptoms can be divided into three subtypes, which can be difficult to distinguish: (1) primary enduring (or deficit), (2) primary non-enduring, and (3) negative symptoms that are secondary to other causes, such as depression, positive symptoms, EPS, substance abuse, or iatrogenic effects such as under stimulation during long-term hospitalization. Prior to feeling good experiences, over 70% of schizophrenia patients suffer basic negative symptoms. There are presently no viable treatments for the main Unpleasant effects. Cognitive dysfunction Attention, learning, memory, focus, abstract thinking, and problem solving are all affected by cognitive dysfunction in schizophrenia, which can be highly severe. Cognitive dysfunction can have a significant impact on a person's capacity to function in daily life, and it frequently
Manifests as a drop in school or work performance.

Efficiency on mood symptoms

In schizophrenia, mood symptoms, particularly depression but also mania, can develop. Depressive symptoms are widespread throughout the illness, and they are related to poorer outcomes, reduced social and vocational functioning, lower quality of life, and a higher risk of relapse and suicide. In schizophrenia, the modal rate of comorbid depression has been observed to be 25%. Anomalies in neurotransmission have been used to explain the pathophysiology of schizophrenia. The majority of these theories concentrate upon dopamine, serotonin, and glutamate neurotransmitter abnormalities. Other ideas link aspartate, glycine, and Gamma-aminobutyric acid (GABA) to schizophrenia's neurochemical imbalance. Abnormal activity at dopamine receptor sites (specifically D_2) is thought to be associated with many of the symptoms of schizophrenia. Four dopaminergic pathways have been Implicated. The substantia nigra is the start of the nigrostriatal pathway, which leads to the caudate nucleus. Low dopamine levels in this pathway are considered to cause motor symptoms through affecting the extrapyramidal system. The mesolimbic pathway, which extends from the ventral tegmental area (VTA) to limbic areas, may play a role in the positive symptoms of schizophrenia in the presence of excess dopamine. The mesocortical circuit connects the VTA to the cortex. Negative symptoms and cognitive impairments in schizophrenia are thought to be caused by low mesocortical dopamine levels. The Tuberoinfundibular pathway travels from the hypothalamus to the pituitary gland. Increased prolactin levels and, as a result, galactorrhea, amenorrhea, and lower libido result from a Reduction or blockade of tuberoinfundibular dopamine. The serotonin theory for the genesis of schizophrenia was born out of the observation that lysergic acid diethylamide (LSD) increased the effects of serotonin in the brain. Following study, pharmacological compounds that blocked both dopamine and serotonin receptors were discovered, in contrast to previous treatments that only targeted dopamine receptors. Both positive and negative symptoms of schizophrenia have been claimed to be helped by the newer drugs. Another theory explaining the symptoms of schizophrenia is that glutamate, the brain's principal excitatory neurotransmitter, is activated. This hypothesis was motivated by the observation that phenylciclidine and ketamine, two noncompetitive NMDA/glutamate antagonists, elicit schizophrenia-like symptoms. 6 This indicated that under the normal management of mesocortical dopamine neurons, NMDA receptors are inactive, which could explain why persons with schizophrenia exhibit negative, affective, and cognitive symptoms. In schizophrenia patients, the brain tissue appears to undergo physical changes that can be detected. Individuals at high risk of a schizophrenia episode, for example, have a smaller medial temporal lobe in addition to an increase in the size of the third and lateral ventricles.



Fig 1: Pathophysiology of schizophrenia [4, 5]

Current treatment option for schizophrenia

Various therapy options for the treatment of schizophrenia have recently become accessible and are currently being used in practise. Typically, clinical reports and their ranges or severity levels are used to determine schizophrenia treatment. Patients with schizophrenia who cannot take their medications are more likely to relapse, which may require hospitalization. As a result, it's vital to inform the patient of his illness and current health status. As you are probably aware, schizophrenia is a serious chronic illness that requires lifetime care, thus it is your job to stay informed.

Antipsychotic agents for Schizophrenia

Chlorpromazine, a first-generation antipsychotics (FGAs) medicine, was discovered in 1950 and was widely utilized because it was the only antipsychotic drug available at the time. Chlorpromazine at a higher dose will lower the severity of schizophrenia.. Other medicines of this class, including as loxapine, fluphenazine, perphenazine, and haloperidol, were identified by modifying their structure and activity, however they all have a major side effect, extrapyramidal symptoms, which should not be overlooked. As a result, these drugs are no longer in use. These FGAs pharmaceuticals are also known as typical or conventional medications. Clozapine is a second-generation antipsychotic drug that was discovered in 1970 and is far superior to other agents. It's a dopamine receptor agonist, but it works in a different way. Second-generation antipsychotics (SGAs) are a first-line treatment for schizophrenia that has proven to be successful. Following this, a number of SGAs have been found that may also be effective in reducing the intensity of this disease? This family of medications, originally classified as atypical antipsychotics but now referred to as 2nd generation antipsychotics, was lauded as the first substantial development in schizophrenia therapy in 40 years. These medications appear to outperform first-generation antipsychotics. It is difficult to establish effective rehabilitation programmes in most schizophrenia patients without the use of antipsychotic medications. In the event of an acute psychotic episode, medication should be started right away. Clozapine's effectiveness may be enhanced when used in conjunction with other medications, such as risperidone. Clozapine is a more effective antipsychotic than other antipsychotics. Clozapine was first provided with the count of white blood cells (WBCs) being monitored. If agranulocytosis develops as a result of the high dose, the clozapine must be stopped. If schizophrenia has progressed to a severe stage, combination therapy, such as a combination of SGAs and FGAs or other drugs, may be beneficial. Second-generation antipsychotics (SGAs) have few noticeable side effects, although the most common one is weight gain. Furthermore, excessive doses of clozapine have been linked to significant side effects such seizures. So, these are some of the most regularly used antipsychotics.

First generation antipsychotics

When the dopamine neurotransmitter mechanism is triggered, these pathways are also activated, resulting in positive schizophrenia symptoms as indicated in FIGURE 1. However, FGAs suppress the function of the neurotransmitter dopamine receptor 2, preventing these pathways from being activated and inhibiting schizophrenia.



Fig 2: Mechanism Pathways for First generation Anti-psychotics (FGAs).

Second generation antipsychotics

Atypical antipsychotic agents are also a name for SGAs. SGAs were recently developed and have been shown to improve schizophrenia treatment while posing less dangers. Many schizophrenia drugs have higher dangers and lower efficacy. Clozapine, for example, is a powerful serotonin antagonist that binds to the 5-HT, 2A/2C receptor subtypes. It also has some affinity for dopaminergic (D2) receptors, although only to a minor degree. Clozapine has an antagonistic impact on D2 receptors in the mesolimbic pathway and 5-HT/2A receptors in the

frontal cortex when used in a combined form. The activation of mesolimbic pathways as well as the frontal cortex are both reduced when D2 and 5-HT receptors are blocked. Positive symptoms are relieved by D2 antagonists, while negative ones are relieved by 5-HT/2A antagonists. One major issue with the usage of these medications is that repeated use of these agents at regular doses generates super-sensitivity in patients, resulting in no additional effect being created in the patient. As a result, we must increase the dose to cure or to have an effect. There are several drugs that increase dopamine levels in the body and cause schizophrenia in patients, such as cocaine, amphetamines, and other stimulants.

Newer antipsychotics known as "atypical antipsychotics" have a lower risk of extrapyramidal adverse effects than older antipsychotics. Antipsychotics currently accessible in the U. S. are listed in Table 4. Medicine nonadherence is a major issue; in one recent study, 74% of patients stopped taking their medication after 18 months. 16 Noncompliance frequently results in a recurrence of symptoms. Because of their decreased likelihood of neurologic adverse effects, atypical antipsychotics were once expected to aid adherence. However, meta-analyses have indicated that atypical antipsychotics had no better drop-out rates or relapse prevention than neuroleptics. 17,18 Atypical antipsychotics are also superior than high doses (more than 12 mg per day) of haloperidol (Haldol) in respect of symptom scores and drop-out rates, according to meta-analyses; when the dose of haloperidol was less than 12 mg per day, there was no benefit. To put it another way, many of the reported benefits of atypical antipsychotics were due to the use of high doses of first-generation antipsychotics in randomized trials. Evidence suggests that delaying the start of antipsychotic therapy can have a long-term negative impact on psychotic episodes and social adjustment. If psychiatric resources are inadequate, family physicians should consider initiating medicines instead of antipsychotic therapy.

Psychosocial Treatments

Individuals, group and family therapy for people with schizophrenia have been established. Individual family therapy, group psychoeducation, and family group therapy are all examples of family interventions. Support, education about the illness, and alternatives for lowering critical and emotionally overinvolved attitudes and behaviors toward patients are all available through these interventions. The best empirical support for alleviating symptoms and lowering hospitalizations comes from family therapy. These therapies are based on early research that found that family situations with a lot of "expressed emotion" (either critical and rejecting or emotionally overinvolved) were linked to recurrence in schizophrenia patients. Multiple studies have indicated that family interventions reduce relapse rates and improve symptoms, medication adherence, and functioning. However, numerous family intervention experiments were shown to have problems in a recent study, indicating that more research is needed. A variety of psychosocial rehabilitation treatments have been discovered to improve the quality of life of schizophrenia patients. The Intensive Psychiatric Rehabilitation Treatment, which is a programmer that teaches patients living, employment, and social skills, has improved patients' functioning. Supported employment programmes have increased the number of hours worked and total wages paid41, and in-home crisis intervention has showed potential in reducing treatment dropout rates. Individual cognitive behavior therapy for schizophrenia has been found in studies to improve both positive and negative symptoms, but no evidence that it lowers relapse rates.

Drugs used in treatment of schizophrenia

1. Clozapine

Clozapine is a one-of-a-kind antipsychotic that can be considered a separate 'third class' of antipsychotic. It is the only antipsychotic medicine that has been shown to work in schizophrenia patients who have failed to respond to other treatments (TRS). Clozapine produces significant antipsychotic action at a 65 percent threshold of striatal D2 receptor blockade, suggesting that other receptors or mechanisms contribute to its therapeutic impact beyond D2 receptor inhibition in the striatum. The precise mechanism of clozapine's better effectiveness in TRS has not been determined, but about 50–60 percent of individuals with schizophrenia who are refractory to other antipsychotics will respond to it.

Clozapine use, on the other hand, varies greatly by geography, with most countries having a lower prevalence of clozapine use than the 30% of patients who are likely to benefit from it, and there is substantial evidence that it is only used after a several-year delay. 21 This is partially owing to the nature and severity of the side effects it might induce, such as agranulocytosis, which affects about 0.8 percent of clozapine-treated patients in the UK and is linked to a death rate of 1 in 10,000. Clozapine is only given in the United Kingdom in conjunction with weekly white cell count measurements for the first 18 weeks of treatment, followed by fortnightly white cell count measurements for the next 34 weeks And then followed by monthly white cell counts for as long as the patient is maintained on clozapine. It is likely that the fear of adverse medication reactions (by clinicians and patients alike) and the inconvenience of therapeutic monitoring of full blood counts (FBCs) so early in the course of Clozapine use are factors contributing to this delay.

2. Paliperidone

Paliperidone, the active metabolite of risperidone, is available in oral and LAI forms, with efficacy, tolerability, and a delay in duration to relapse in schizophrenia in both. It is not metabolized by the liver, hence it is safe to use in patients with hepatic impairment and has a low risk of pharmacokinetic drug interactions. Paliperidone is also approved for the treatment of schizoaffective disorder's psychotic and manic symptoms. Its side effects are

comparable to those of the parent molecule risperidone, including weight gain, hyperprolactinemia, and EPSEs at higher doses, as well as tardive dyskinesia in some cases. EPSEs are more likely with doses of 9–12 mg oral Paliperidone (equal to 4–6 mg risperidone daily). 6–9 mg once daily (equivalent) is the therapeutic dose range.
Paliperidone palmitate is the LAI formulation, which achieves active serum levels within
Days of initiation and allows deltoid, rather than gluteal muscle administration.

3. Asenapine

Although Asenapine has shown efficacy in the acute and maintenance stages of schizophrenia treatment, as well as the treatment of acute mania in BPAD, it is currently only licensed in the United Kingdom for the treatment of mania. Asenapine has a high affinity for a variety of serotonin receptors, including 5-HT2A, 5-HT2C, 5-HT7, and 5-HT1A antagonism, as well as powerful D2 and D3 antagonism and modest histamine (H) 1 antagonism.
If Asenapine is consumed, it is rendered inactive due to first-pass metabolism. As a result, it's only available in the form of an orally disintegrating tablet, which is absorbed through the oral mucosa. Antipsychotic or dispersible tablets such as olanzapine, risperidone, and aripiprazole, on the other hand, must be swallowed to be effective. Patients should be informed that Asenapine cannot be consumed and that they should refrain from eating or drinking for at least 10 minutes after therapy.
Asenapine does not need dose titration and can be started at a dose of 5 mg twice daily for acute schizophrenia, with doses approximately 10 mg twice daily showing benefit in preventing relapses. Because asenapine has a half-life of 24 hours, it could potentially be administered once a day, although the efficacy of such a prescription has yet to be determined in clinical trials. It appears to be a metabolically neutral antipsychotic that has minimal effect on prolactin levels and has a low proclivity for weight gain (however there is some evidence for a higher proclivity for weight gain in acute mania). It can cause akathisia (which is more common with 10 mg twice-daily dosing than with 5 mg twice-daily dosing), sedation, and taste disturbance.

4. Lurasidone

Lurasidone is an approved therapy for bipolar depression in the United States, and it has been demonstrated to be effective as an additional treatment for schizophrenia.
Lurasidone exhibits complete D2 antagonistic activity and is an antagonist at 5HT2A and
5HT7 receptors, with minor agonism at 5-HT1A receptors and minimal affinity for 5HT2C, H1, and muscarinic receptors. Lurasidone is a once-daily medication that makes it easier to take. Adults should start with 37 mg once daily and gradually increase to a max of 148 mg once daily if necessary. A dose range of 37–148 mg per day is recommended for schizophrenia, with a lower dose range of 18.5–120 mg per day suggested for bipolar depression (Lurasidone at lower doses of 20–60 mg per day has been shown to be as clinically effective in bipolar depression as at higher doses of 80–100 mg/day). Lurasidone is metabolized by CYP3A4 enzymes, hence it should be used in smaller doses, when used with concomitant CYP3A4 inhibitors (e.g. diltiazem, erythromycin).
Lurasidone is usually well tolerated, with few reports of weight gain or metabolic problems. Despite being a full D2 antagonist, it is not related to higher incidences of EPSEs (excluding akathisia) or hyperprolactinemia, as is the case with Asenapine. It is accompanied with akathisia (increased rate at doses of 120 mg or greater), sedation, and nausea, but unlike asenapine, it is not related to higher incidences of EPSEs (excluding akathisia).

5. Olanzapine

Olanzapine is an antipsychotic medication used to treat psychotic diseases such as schizophrenia and manic depressive illness in adults and children aged 13 and up (manic depression). Olanzapine is also used in combination with fluoxetine (Prozac) to treat depression in adults and children aged 10 and up who have bipolar I disorder. Olanzapine can also be used for topics that aren't covered in this article. Olanzapine may cause high blood glucose as an adverse effect (hyperglycemia). If you have diabetes, you should monitor your blood glucose levels on a daily basis. You'll gain weight or have raised cholesterol and triglycerides (fat types) if you take olanzapine, especially if you're a teen. On a daily basis, blood tests are also required. Do not stop taking olanzapine suddenly, even if you are feeling fine. Stopping abruptly can have disastrous results. Olanzapine is commonly used in conjunction with other antipsychotic or antidepressant medications. Follow all medicine instructions and read all medication guides you receive. Consult your doctor before changing your dose or dosing plan.

6. Quetiapine

Quetiapine is an antipsychotic drug used to treat schizophrenia in adults and children aged 13 and up. Quetiapine is a drug used to treat mental disorders such as manic depression in adults and children over the age of ten. Adults with substantial emotional disturbances are given quetiapine in combination with antidepressants. Quetiapine is also used for a variety of other purposes that aren't mentioned in this drug guide. Instead than crushing, chewing, or breaking the tablet, swallow it whole.
Quetiapine may cause you to have a high blood sugar level (hyperglycemia). Check your blood glucose levels on a daily basis if you have diabetes. Drink plenty of water while taking quetiapine. In a kid or teenager taking quetiapine, blood pressure may need to be checked often. You should not abruptly discontinue using quetiapine. Stopping abruptly may aggravate your issue. This medicine may interfere with a drug-screening urine test,

causing erroneous results. Tell the lab personnel that you're only taking quetiapine. Store at a cool, dry temperature away from moisture and heat.

7. Ziprasidone

Ziprasidone is a type of antipsychotic drug. Ziprasidone is an oral drug used to treat the manic symptoms of schizophrenia and bipolar disorder (manic depression). Ziprasidone injections are used to quickly treat agitation in persons with schizophrenia. Ziprasidone is also used for a number of additional conditions that aren't included in this medication guide. Ziprasidone oral is a drug that is administered orally. Ziprasidone injection is given to a muscle. A healthcare provider will give you this injection if you are unable to take the medicine by mouth. It's best to take Ziprasidone with food. Swallow the capsule completely.

If you have diabetes, monitor your blood sugar levels on a regular basis while taking ziprasidone. Your symptoms could take a few weeks to improve. Do not stop taking ziprasidone suddenly, even if you feel fine. Continue to take the medication as directed and notify your doctor if your condition does not improve.

8. Risperdal

Risperidone is an antipsychotic medication that operates by affecting brain chemistry. Risperdal is a schizophrenia medicine that is prescribed to adults and children aged 13 and higher. Risperdal is also used to treat the symptoms of bipolar disorder (manic depression) in adults and children older than 10 years old. Risperdal is also used to treat autistic youngsters aged 5 to 16 years old who are irritable. Risperdal is an antipsychotic drug that can be taken with or without food. When you're ready to use the Risperdal M-Tab orally disintegrating tablet, take it out of the container. Place the pill in your mouth without chewing and let it to dissolve. As the tablet dissolves, swallow it multiple times. Carefully measure liquid medicine. Use the accompanying dosage syringe or a pharmaceutical dose-measuring equipment (not a kitchen spoon). Risperdal liquid should not be mixed with cola or tea.

Conclusion

Recent advancements in schizophrenia genetic research are a significant step forward, but their practical implications, such as useful clinical predictive genetic testing, are still a long way off. This is due to a variety of factors. To begin with, each of the found genes gives just a minor degree of mental illness vulnerability, with relative risks in the range of two. Second, despite the discovery of genes that appear to increase susceptibility, the exact genetic alterations responsible for pathogenesis within them have yet to be identified, and the importance and mechanism of these genes in conferring mental illness susceptibility remain unknown.. This paper aimed to give genetic counsellors an overview of some of the hallmark characteristics of schizophrenia, as well as issues in diagnosis and treatment, as well as an update on the state-of-the-art in rapidly advancing fields of research into genetic and environmental contributors to schizophrenia. This paper aims to provide genetic counselors with a foundation for further reading and an awareness of some of the most critical areas in which genetic counseling may have significant psychosocial impact for families touched by schizophrenia.

One of the most important aims of pharmacological research should be to develop new ideal antipsychotic drugs with low associated risk, rapid onset of action, more effective treatment for negative, cognitive, and affective symptoms, improved efficacy against positive symptoms, reduced or even reversed cumulative morbidity, and improved relapse rates. 189 Further progress is dependent on the development of a variety of basic and clinical neuroscience methods, although given current advancements, future improvement is anticipated to be quite swift. To improve our understanding of the molecular and functional pathophysiological pathways operative in schizophrenia, we will need to continue our research efforts and collaborate with academic and industry laboratories. According to the findings of this study, schizophrenia is a difficult, chronic mental health problem characterized by a wide range of symptoms, including delusions, hallucinations, and abnormal speech or behavior. Schizophrenia is a complicated disorder that requires rapid medical attention. Although current pharmaceutical and nonpharmacological therapeutic choices can assist patients improve adaptive functioning, future research is hoped to fill in treatment gaps and possibly lead to a schizophrenia cure. Individual responses to antipsychotic medicine are variable, and the inability to predict response leads to a trial-and-error therapy method. Clozapine's effects in TRS have yet to be replicated, and its mechanism of action has proven difficult to define and reproduce in other antipsychotic drugs for schizophrenia.

Abbreviations

BPAD: Bipolar Affective Disorder
TRS: Treatment Resistance Schizophrenia
FGA: First Generation Antipsychotics
EPSE: Extra Pyramidal Side Effects

Acknowledgements

I would like to extend my special thanks to Sandip Institute of Pharmaceutical Sciences. The assistance provided by Dr. Laxmikant Borse, Dr. Atul Bendale and Dr. Anil Jadhav is really appreciated.

References

1. AbdelMalik P, Husted J, Chow EW, Bassett AS. Childhood head injury and expression of schizophrenia in multiply affected families. Arch Gen Psychol,2003:60(3):231-236.
2. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia. Arch Gen Psychol,2003:60:565-571. Armenteros,
3. Fennelly JL, Hallin BWA, Adams PB, Pomerantz P, Michell M, Sanchez LE, Campbell M. Schizophrenia in hospitalized adolescents: Clinical diagnosis, DSM-IIIR, DSM-IV, and ICD-10. Psychopharmacol Bull,2005:31(2):383-387.
4. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: Examination of the evidence. Br JPsychiatry,2004:184:110-117.
5. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. Washington, DC: American Psychiatric Association. Austin, J. C, 2004.
6. Bromet EJ, Fennig S. Epidemiology and natural history of schizophrenia. BiolPsychiatry,1999:46:871-81.
7. Wahlberg KE, Wynne LC, Hakko H, Laksy K, Moring J, Miettunen J, *et al*. Interaction ofgenetic risk and adoptive parent communication deviance: longitudinal prediction of adoptee psychiatric disorders. Psychol Med,2004:34:1531-41.
8. Tienari P, Wynne LC, Sorri A, Lahti I, Laksy K, Moring J, *et al*. Genotypeenvironmentinteraction in schizophrenia-spectrum disorder. Long-term follow-up study of Finnish adoptees. Br J Psychiatry,2004:184:216-22.
9. Tienari P, Wynne LC, Moring J, Laksy K, Nieminen P, Sorri A, *et al*. Finnish adoptivefamily study: sample selection and adoptee DSM-III-R diagnoses. Acta Psychiatr Scand,2000:101:433-43.
10. Wahlberg KE, Wynne LC, Oja H, Keskitalo P, Pykalainen L, Lahti I, *et al*. Gene-environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of Schizophrenia. Am J Psychiatry,1997:154:355-62.
11. Biedermann F, Fleischhacker WW. Emerging drugs for schizophrenia. *Expert Opin Emerg Drugs*,2011:16:271-282.
12. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versusfirst-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet*,2009:373:31-41.
13. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emissiontomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. *Arch Gen Psychiatry*,1992:49:538-544.
14. Kahn RS, Sommer IE, Murray RM, *et al*. Schizophrenia. Nat. Rev. Dis. Primers. 15067 (2015). Freedman R. Schizophrenia. N. Engl. J. Med,2011:349(18):1738-1749.
15. http://www.schres-journal.com/ issue/S0920-9964(00)X0120-X Weinberger DR, Levitt P.
16. Neurodevelopmental Origins of Schizophrenia. Schizophrenia,2011:393-412.
17. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int. Rev. Psychiatry,2010:22:417.
18. Messias E, Chen CY, Eaton WW. Epidemiology of Schizophrenia: Review of Findings and Myths. The Psychiatr. Clin. North. Am,2007:30(3):323-338.
19. Gründer G, Cumming P. The Dopamine Hypothesis of Schizophrenia. The Neurobiologyof Schizophrenia, 2007, 109-124.
20. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology,2009:20(3):201-225.
21. Howes OD Murray RM Schizophrenia: an integrated socio developmental-cognitive model *Lancet*,2014:383:1677-87.
22. Marder SR, Van Putten T. Antipsychotic medications. In: Schatzberg AF, Nemeroff CB (eds). *The American Psychiatric Press Textbook of Psychopharmacology*. American Psychiatric Press, Inc.: Washington, DC, 1995, 247-261.
23. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C *et al*. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. *Biol Psychiatry*,1993:33:227-235.
24. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevatesdopamine receptor binding in brain. *Science*,1977:196:326-328.
25. Fleminger S, Rupniak NM, Hall MD, Jenner P, Marsden CD. Changes inapomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. *Biochem Pharmacol*,1983:32:2921-2927.
26. Moore H, Todd CL, Grace AA. Striatal extracellular dopamine levels in rats withhaloperidol-induced depolarization block of substantia nigra dopamine neurons. *J Neurosci*,1998:18:5068-5077.
27. Waddington J, Casey D. Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). *Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice*. Butterworth-Heinemann: Woburn, MA, 2000, 3-13.
28. Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychoticdrug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. *Mol Psychiatry*,1999:4:418-428.
29. https://www.drugs.com/condition/schizophrenia.html

30. https://www.drugs.com/condition/schizophrenia.html
31. https://www.drugs.com/mtm/ziprasidone.html
32. https://www.drugs.com/risperdal.html
33. Marwaha S, Johnson S. Schizophrenia and employment. *Soc Psychiatry Psychiatr Epidemiol*,2004:39:337-349. https://doi.org/10.1007/s00127-004-0762-4
34. Axel M. "Ten borderline cases: a report on the question of pseudoneurotic schizophrenia." Psychiat. Quart.,1955:29:555-87.
35. Bellak L. Schizophrenia: A Review of the Syndrome. New York: Logos Press.
36. Bleuler E. Dementia Praecox or the Group of Schizophrenias. English Translation. New York: Int. Univ. Press, 1950.
37. Brain Lord. "The neurology of language." Brain,1961:84:145-65.CrossRef
38. Brain Lord. "Some reflections on brain and mind." Ibid.,1963:86:399.
39. Cameron N. "Reasoning, regression and communication in schizophrenics." Psychol. Monogr.,1938:50:1-33.
40. Cameron N. "Deterioration and regression in schizophrenic thinking." J. abnorm. soc. Psychol.,1939:34:265-70.
41. Chapman J, McGhie A. "An approach to the psychotherapy of cognitive dysfunction in schizophrenia." Brit. J. med. Psychol.,1963:36:253-60.
42. Chapman J, McGhie A "Echopraxia in schizophrenia." Brit. J. Psychiat.,1964:110:365-74.
43. Critchley M. The Language of Gesture. London: Arnold, 1939.
44. Critchley M. The Parietal Lobes. London: Arnold. Google, 1953.
45. Critchley M. "The neurology of psychotic speech." Brit. J. Psychiat.,1964:110:353-64.
46. Crookes TG. "Size constancy and literalness in Rorschach test." Brit. J. med. Psychol.,1957:30:99-106.
47. Curran D, Partridge M. Psychological Medicine (4th Ed.). Edinburgh: Livingstone.
48. Fish FJ. Schizophrenia. Bristol: Wright.Forer, B. R. (1950). "The latency of latent schizophrenia." J. project. Tech.,1962:14:297.
49. Gillies H. "The schizophrenic disorders." In Modern Practice in Psychological Medicine (ed. Rees), 1949, 296-315. London: Butterworth.
50. Gillies, H. (1958). "The clinical diagnosis of early schizophrenia." In: Topics in Psychiatry (ed. Rodger, Mowbray, and Roy,), 1958, 47-56. London: Cassell$.
51. Bottas A, Cooke RG, Richter MA. Comorbidity and pathophysiology of obsessive–compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? Journal of Psychiatry and Neuroscience,1993:30:187.
52. Buckley, PF, Miller, BJ, Lehrer, DS, Castle, DJ (2009). Psychiatric comorbidities and schizophrenia. Schizophrenia Bulletin,2009:35:383-402.CrossRefGoogle Scholar
53. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, *et al*. *In vitro* and *in vivo* biochemistry of olanzapine: a novel, atypical antipsychotic drug. Journal of Clinical Psychiatry,1997:58(10):28-36.
54. Catapano F, Perris F, Fabrazzo M, Cioffi V, Giacco D, De Santis V. Obsessive–compulsive disorder with poor insight: a three-year prospective study. Progress in Neuro-Psychopharmacology and Biological Psychiatry,2010:34:323-330.
55. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry,2008:69:720-731.
56. Fink M, Taylor MA. The many varieties of catatonia. European Archives of Psychiatry and Clinical Neuroscience,2001:251(1):I8-I13.
57. Green, MF, Nuechterlein, KH, Kern, RS, Baade, LE, Fenton, WS, Gold, JM, *et al*. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Clinical Neurosciences,200812:91-94.
58. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, *et al*. The MATRICS Consensus Cognitive Battery, part 2: co-norming and Psychometric and Standardization Study. American Journal of Psychiatry,2008:165:221-228.
59. Guillem F, Satterthwaite J, Pampoulova T, Stip E. Relationship between psychotic and obsessive compulsive symptoms in schizophrenia. Schizophrenia Research,2009:115:358-362.
60. Hwang MY, Kim SW, Yum SY, Opler LA. Management of schizophrenia with obsessive–compulsive features. Psychiatric Clinics of North America,2009:32:835-851.
61. Hwang MY, Morgan JE, Losconzcy MF. Clinical and neuropsychological profiles of obsessive–compulsive schizophrenia: a pilot study. Journal of Neuropsychiatry and standardization. American Journal of Psychiatry,2000:165:214-220.